Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced that the American Society of General Surgeons (ASGS) endorsed Cellvizio® as integral to the comprehensive assessment and therapeutic decisions for the treatment of Barrett’s esophagus and Gastroesophageal Reflux Disease (GERD). The Position Statement from the ASGS will be available on the ASGS website.
http://www.prnewswire.com/news-releases/cellvizio-endorsed-by-the-american-society-of-general-surgeons-as-integral-to-the-care-of-patients-with-gastroesophageal-reflux-disease-gerd-and-barretts-esophagus-592039111.html
Cellvizio® Endorsed by the American Society of General Surgeons as Integral to the Care of Patients with Gastroesophageal Reflux Disease (GERD) and Barrett's Esophagus